NEKTAR THERAPEUTICS Form 8-K October 11, 2006

## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT** 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 5, 2006

# **NEKTAR THERAPEUTICS**

(Exact name of Registrant as specified in its charter)

**Delaware** (State or other jurisdiction

0-24006 (Commission File Number) 94-3134940 (IRS Employer

of incorporation)

150 Industrial Road

**Identification No.)** 

San Carlos, California 94070

(Address of principal executive offices and Zip Code)

Registrant s telephone number, including area code: (650) 631-3100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

## Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K

### Item 1.01 Entry into a Material Definitive Agreement.

On March 13, 2006, Nektar Therapeutics (the Company ) entered into a Transition and Retirement Agreement (the Retirement Agreement ) with its former President and Chief Executive Officer, Ajit S. Gill. On October 5, 2006, the Company and Mr. Gill entered into an amendment to the Retirement Agreement pursuant to which (i) Mr. Gill s continuing consulting service obligation to the Company through June 30, 2009 (Original Service Period) was discontinued, (ii) Mr. Gill s unvested outstanding stock options and restricted stock units were accelerated, and (iii) the exercise period of certain of Mr. Gill s stock options were extended for the same period as if Mr. Gill had continued service through the Original Service Period.

# Edgar Filing: NEKTAR THERAPEUTICS - Form 8-K

#### **SIGNATURES**

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

By: /s/ Nevan C. Elam Nevan C. Elam Senior Vice President Corporate

Operations and General Counsel

Date: October 11, 2006